Pyridoxine responsiveness in novel mutations of the PNPO gene by Plecko, Barbara et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Pyridoxine responsiveness in novel mutations of the PNPO gene
Plecko, Barbara; Paul, Karl; Mills, Philippa; Clayton, Peter; Paschke, Eduard; Maier, Oliver;
Hasselmann, Oswald; Schmiedel, Gudrun; Kanz, Simone; Connolly, Mary; Wolf, Nicole; Struys, Eduard;
Stockler, Sylvia; Abela, Lucia; Hofer, Doris
Abstract: OBJECTIVE: To determine whether patients with pyridoxine-responsive seizures but normal
biomarkers for antiquitin deficiency and normal sequencing of the ALDH7A1 gene may have PNPO mu-
tations. METHODS: We sequenced the PNPO gene in 31 patients who fulfilled the above-mentioned
criteria. RESULTS: We were able to identify 11 patients carrying 3 novel mutations of the PNPO
gene. In 6 families, a homozygous missense mutation p.Arg225His in exon 7 was identified, while 1
family was compound heterozygous for a novel missense mutation p.Arg141Cys in exon 5 and a deletion
c.279290delinexon3.Pathogenicityoftherespectivemutationswasprovenbyabsencein100controlallelesandexpressionstudiesinCHO−
K1celllines.Theresponsetopyridoxinewaspromptin4, delayedin2, onEEGonlyin2, andinitiallyabsentinanother2patients.Twounrelatedpatientshomozygousforthep.Arg225Hismutationexperiencedstatusepilepticuswhenswitchedtopyridoxal5′−
phosphate(PLP ).CONCLUSIONS : ThisstudychallengestheparadigmofexclusivePLPresponsivenessinpatientswithpyridoxal5′−
phosphateoxidasedeficiencyandunderlinestheimportanceofconsecutivetestingofpyridoxineandPLPinneonateswithantiepilepticdrug−
resistantseizures.PatientswithpyridoxineresponsebutnormalbiomarkersforantiquitindeficiencyshouldundergoPNPOmutationanalysis.
DOI: 10.1212/WNL.0000000000000344
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-104719
Published Version
Originally published at:
Plecko, Barbara; Paul, Karl; Mills, Philippa; Clayton, Peter; Paschke, Eduard; Maier, Oliver; Has-
selmann, Oswald; Schmiedel, Gudrun; Kanz, Simone; Connolly, Mary; Wolf, Nicole; Struys, Eduard;
Stockler, Sylvia; Abela, Lucia; Hofer, Doris (2014). Pyridoxine responsiveness in novel mutations of the
PNPO gene. Neurology, 82(16):1425-1433. DOI: 10.1212/WNL.0000000000000344
Barbara Plecko, MD
Karl Paul
Philippa Mills, PhD
Peter Clayton, MD, PhD
Eduard Paschke, PhD
Oliver Maier, MD
Oswald Hasselmann, MD
Gudrun Schmiedel, MD
Simone Kanz, MD
Mary Connolly, MB Bch
Nicole Wolf, MD
Eduard Struys, PhD
Sylvia Stockler, MD, PhD
Lucia Abela, MD
Doris Hofer, MMS
Correspondence to
Dr. Plecko:
barbara.plecko@kispi.uzh.ch
Editorial, page 1392
Supplemental data
at Neurology.org
Pyridoxine responsiveness in novel
mutations of the PNPO gene
ABSTRACT
Objective: To determine whether patients with pyridoxine-responsive seizures but normal bio-
markers for antiquitin deficiency and normal sequencing of the ALDH7A1 gene may have PNPO
mutations.
Methods:We sequenced the PNPO gene in 31 patients who fulfilled the above-mentioned criteria.
Results:Wewere able to identify11patients carrying3novelmutations of thePNPOgene. In6 families,
a homozygous missense mutation p.Arg225His in exon 7 was identified, while 1 family was compound
heterozygous for a novel missense mutation p.Arg141Cys in exon 5 and a deletion c.279_290del in
exon 3. Pathogenicity of the respective mutations was proven by absence in 100 control alleles and
expression studies in CHO-K1 cell lines. The response to pyridoxine was prompt in 4, delayed in 2, on
EEG only in 2, and initially absent in another 2 patients. Two unrelated patients homozygous for the
p.Arg225His mutation experienced status epilepticus when switched to pyridoxal 59-phosphate (PLP).
Conclusions: This study challenges the paradigm of exclusive PLP responsiveness in patients with
pyridoxal 59-phosphate oxidase deficiency and underlines the importance of consecutive testing
of pyridoxine and PLP in neonates with antiepileptic drug–resistant seizures. Patients with pyr-
idoxine response but normal biomarkers for antiquitin deficiency should undergo PNPO mutation
analysis. Neurology® 2014;82:1425–1433
GLOSSARY
AASA5 a-aminoadipic semialdehyde;PA5 pipecolic acid; PLP5 pyridoxal 59-phosphate; PNPO5 pyridoxal 59-phosphate oxidase.
In 2005 and 2006, the molecular background of the 2most prevalent forms of vitamin B6-dependent
epilepsies due to inborn errors of metabolism, namely pyridoxal 59-phosphate oxidase (PNPO)
deficiency and pyridoxine-dependent epilepsy due to antiquitin deficiency, was elucidated.1,2 Clin-
ically both disorders present with neonatal mixed multifocal myoclonic tonic seizures that may be
accompanied by primary poor adaptation, epileptic encephalopathy, and high mortality if causal
treatment is delayed. So far, the clinical response to different forms of vitamin B6 has been used to
guide further biochemical and molecular workup. Patients with antiquitin deficiency are respon-
sive to pyridoxine and have elevated a-aminoadipic semialdehyde (AASA), while patients with
PNPO deficiency are in need of the active vitamer pyridoxal 59-phosphate (PLP) and lack a
specific biomarker.1,3–5 To date, few mutations of the PNPO gene have been further characterized
by in vitro expression studies.1,6,7
With larger cohorts undergoing biochemical and molecular testing, we observed that a minority of
patients with neonatal pyridoxine-responsive seizures did not show the typical biomarker profile of
antiquitin deficiency and had wild-type sequences of the ALDH7A1 gene. This led us to the
hypothesis that these patients may have mutations of the PNPO gene that allow some residual
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function and that these patients may benefit from
higher substrate concentrations. We describe 11
children of 7 families with 3 novel PNPO gene
mutations with a complete or partial pyridoxine
response and expression of mutations in CHO1
cell lines.
METHODS Standard protocol approvals, registrations, and
patient consents. Patient samples were sent from different pediatric
centers to the Laboratory of Metabolic Diseases, Department of Pedi-
atrics at the Medical University Hospital Graz for biochemical and
genetic workup of pyridoxine-responsive seizures. In all patients,
written informed consent of parents had been given for molecular
analysis of the ALDH7A1 gene.
Following diagnostic workup, we identified a total of 34 pa-
tients suspected to have pyridoxine-responsive seizures by their
referring physician, who had normal biomarkers and wild-type
sequence analysis of the ALDH7A1 gene.
To test our hypothesis, we selected one patient (2b) out of this
cohort in whom there was information on a clear pyridoxine response
and recurrence of seizures upon a controlled withdrawal.We contacted
the referring physician and asked for written informed consent of the
parents of patient 2b for molecular analysis of the PNPO gene. Having
identified sequence anomalies of the PNPO gene in this first patient,
we subsequently contacted other referring physicians and performed
analysis of the PNPO gene in another 30 DNA samples as soon as
written informed consent for the molecular analysis of the PNPO gene
of the parents had been obtained.
In those with sequence anomalies of the PNPO gene, we
asked for detailed information on patient history and results of
previous metabolic investigations. No patient underwent a spinal
tap for reasons related to this study.
Details on methods regarding biochemical analyses, genotyp-
ing, cloning of the PNPO gene, site-directed mutagenesis, tran-
sient CHO-K1 cell transfection, cell cultures, and enzyme assays
are provided as e-Methods (tables e-1 and e-2 on the Neurology®
Web site at Neurology.org).
RESULTS Among the 31 patients analyzed, we were
able to identify 3 novel mutations of the PNPO gene
in 9 living patients from 7 unrelated families. In 2 fam-
ilies, the first child had died due to therapy-resistant
seizures. Details on clinical data, biochemical
investigations, and mutation analysis are provided in
tables 1–3.
Phenotype, EEG findings, and cranial imaging. Four out of
11 patients were born prematurely (,full 36 gestational
weeks). All patients presented in the neonatal period with
recurrent bilateral myoclonic and tonic jerks that were in
single patients accompanied by rolling eye movements
and desaturation. Neonatal EEG records were available
in 9/11 patients and showed burst-suppression patterns
in 5 and discontinuous tracings in 4 at week of gestation
37 to 39 and were considered abnormal.
Ten of eleven patients had a first pyridoxine admin-
istration within their first week of life, while in one the
first pyridoxine administration was delayed to week 6
and in 1 deceased sibling no data were available. Pyridox-
ine administration led to prompt cessation of seizures in
4 patients, delayed seizure reduction over several days
in 2, initial improvement on EEG only in another 2,
and had no effect in 2 other patients, one of them receiv-
ing a single 100-mg IV dose administration only. One of
these 2 initially unresponsive patients underwent a sec-
ond pyridoxine trial at age 7 months with prompt inter-
ruption of seizures. In one patient, no details on the first
pyridoxine administration are available. One patient
underwent a formal pyridoxine withdrawal at age
3 months with seizure recurrence within 12 hours and
accompanying encephalopathy. Two patients developed
status epilepticus as soon as pyridoxine was replaced by
an identical dose of PLP at the scheduled time of medi-
cation administration. Of the 9 alive patients, 6 are on
pyridoxine monotherapy, while 3 have comedication
with variable antiepileptic drugs. Breakthrough seizures
while on pyridoxine were observed in 5 out of 9 patients
alive at some point in time. Cranial MRI revealed bilat-
eral encephalomalacia in 1 patient andmild brain atrophy
in 2 others. Cranial MRI or ultrasound was normal in 5
and 4 patients, respectively.
Overall outcome was good in 5 unrelated patients at
age 1 8/12 years, 1 5/12 years, 6 10/12 years, and
26 years, 2 of them having been index cases. Two
patients had global developmental delay and needed spe-
cial care or support at school. Two patients with mark-
edly delayed continuous administration of pyridoxine
had severe neurologic sequelae and 2 affected siblings
from 2 unrelated families have died in the absence of
continuous pyridoxine treatment.
Biochemical analyses. Biochemical testing was performed
in samples prior to pyridoxine administration unless out-
lined otherwise (table 2). AASA or pipecolic acid (PA) as
biomarkers for antiquitin deficiency were analyzed in all
9 patients alive and found normal except in patient 4a
who had mild elevation of PA in urine at birth and of
AASA on a repeat sample at age 2 months. Increased PA
concentration in plasma was found in patient 6 and
normalized 1 week after the introduction of pyridoxine.
Neurotransmitter analysis showed elevated concentra-
tions of amine metabolites in patient 1b in a pretreat-
ment sample, and was normal in patient 2b and patient
6 before and patient 7 while on pyridoxine. Vanillactate
in urine was available in only 1 patient, patient 6, and
was elevated. Lactate levels in plasma were markedly
elevated in the neonatal period in 3 out of 4 patients
measured. No patient underwent analysis of PLP con-
centrations in CSF.
Genotyping. There was 100% sequence identity between
the patients’ ALDH7A1 gene and the sequence listed for
the human antiquitin gene (NM_001182.3).
Sequence analysis of the PNPO gene revealed a total
of 3 novel mutations in 9 patients from 7 unrelated
families as well as 4 polymorphisms (figure, table 3).
Within all families, cosegregation of the novel mutation
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Table 1 Clinical data on 11 patients/7 families with pyridoxine-responsive mutations of the PNPO gene
Family/
patient Birth/neonatal period
Seizure
onset EEG
1st Administration of
pyridoxine Pyridoxine effect Current medication Clinical course and outcome
1a 33 6/7 GW, Apgar 4/6/8, respiratory
distress, ventilation
1st day
(25 min)
BSP 1st–5th day BDZ 1 PHB 1
PHT, 5th day pyridoxine
1 3 100 mg IV SD
None — †At age 7 days due to SE
1b 35 6/7 GW, Apgar 9/8/8, II° CS
(pathologic CTG, green amniotic fluid),
respiratory distress, ventilation for 3 d,
antibiotics for 3 d
1st day
(24 hours)
BSP 2nd–6th day PHB1 PHT, 6th
and 9th day pyridoxine 100
mg IV SD, from day 9 10 mg/
kg/d
Gradual EEG improvement,
seizure-free on pyridoxine 1
PHB
Pyridoxine 200-150-
150-200 mg/d
monotherapy since age
9 years
Current age 9 9/12 years, global developmental delay,
seizure-free, SE upon switch to identical dose of PLP
after 12-h interval
2a NA NA BSP Yes No effect — †At age 6 months due to refractory seizures
2b 39 2/7 GW, Apgar 9/10/10,
spontaneous delivery, green amniotic
fluid
1st day
(3 hours)
NA 1st day PHB, 2nd day
pyridoxine 100 mg IV SD,
then pyridoxine 5–7 mg/kg/d
No initial effect, effective with
time, encephalopathic upon
pyridoxine withdrawal at age 3
months
Pyridoxine 500-0-500
mg/d (33 mg/kg/d), LVT
4 mg/kg/d, DM type 1
Current age 8 2/12 years, global developmental delay,
recurrent single breakthrough seizures during infancy, SE
upon switch to PLP 12 hours after last pyridoxine, SON
85 at age 6 y
2c 35 4/7 GW, Apgar 7/9/9, green amniotic
fluid, transient respiratory distress,
abdominal distension
2nd day BSP 2nd day pyridoxine 400 mg,
then PHB 30 mg IV SD
Interruption of BSP, seizures
only stopped 1 PHB
Pyridoxine 250-0-250
mg/d (30 mg/kg/d)
monotherapy since age
3 months
Current age 3 10/12 years, normal development
3 39 GW, I° CS, Apgar 8/9/? 6th day Discontinuous
pattern
6th day PHB 1 50 mg
pyridoxine IM SD
Prompt response Pyridoxine 100 mg/d,
SD GBP 1,200 mg/d
Current age 26 years, recurrent SE during infancy and
childhood, recurrent febrile seizures until late
adolescence, normal IQ, seizure-free for last 4 years
4a 36 5/7 GW, Apgar 3/6/7, neonatal
asphyxia and meconium aspiration
syndrome, hypothermia treatment (3 d)
under ventilation
Pathologic
EEG,
followed by
clinical
seizures
Flat tracing,
then BSP
PHB, thiopental,
chloralhydrate, at 6 weeks
pyridoxine 100 mg IV SD,
then 25 mg/kg/d
Prompt response Pyridoxine 100-0-100
mg/d (20 mg/kg/d), LVT
45 mg/kg/d, PHB 5 mg/
kg/d
Current age 4 8/12 years, spastic tetraparesis,
progressive microcephaly, severe global developmental
delay, recurrent single seizure events
4b 37 6/7 GW, Apgar 9/9/10, secondary
respiratory distress and ventilation
(CPAP)
1st day
(11 hours)
Discontinuous
pattern
1st–4th day pyridoxine 100
mg IV, PHB, restarted on day
6 with 30 mg/kg/d
Prompt response Pyridoxine 100-0-100
mg/d (13 mg/kg/d)
monotherapy since age
9 months
Current age 1 8/12 years, unbalanced gait, otherwise
normal development, seizure-free
5 38 1/7 GW, Apgar 9/10/9, postnatal
respiratory distress and asphyxia,
hypothermia (4 d) and antibiotic (6 d)
treatment
6th day
(eventually
1st day)
Discontinuous
pattern
6th day pyridoxine 30 mg/
kg/d PO 1 PHB 7 mg/kg/d
Seizure-free within 3 days Pyridoxine 100-0-150
mg/d (21 mg/kg/d)
monotherapy since age
4 months
Current age 1 5/12 years, normal development, unsteady
gait, seizure-free
6 34 GW, abdominal distension 2nd day NA Received pyridoxine in the
neonatal period at age 7
months, pyridoxine, 100mg IV
No response, prompt response Pyridoxine 300-200-
300 mg/d (50 mg/kg/d)
Current age 8 years, spastic tetraparesis, secondary
microcephaly, cognitive deficit, seizure-free, relapses
upon febrile infections
7 38 2/7 GW, Apgar 9/10/10 1st day
(3 hours)
Discontinuous
pattern
1st day Prompt response to recurrent
IV administration
Pyridoxine 100-100-
200 mg/d (17 mg/kg/d),
OXC 13 mg/kg/d
Current age 6 10/12 years, development normal, seizure-
free over last 7 months
Abbreviations: BDZ 5 benzodiazepines; BSP 5 burst-suppression pattern; CPAP 5 continuous positive airway pressure; CS 5 cesarean section; CTG 5 cardiotocogram; DM 5 diabetes mellitus; GBP 5 gabapentin;
GW 5 gestational week; IM5 intramuscular; LVT 5 levetiracetam; NA5 not available; OXC5 oxcarbazepine; PHB5 phenobarbitone; PHT5 phenytoin; PLP5 pyridoxal 59-phosphate; SD5 single dose; SE5 status
epilepticus; SON 5 Snijders-Omen nonverbal intelligence test.
†Deceased.
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Table 2 Biochemical profiles of 11 patients/7 families with pyridoxine-responsive mutations of the PNPO gene
Patient 1a Patient 1b Patient 2a Patient 2b Patient 2c Patient 3 Patient 4a Patient 4b Patient 5 Patient 6 Patient 7
AASA
Urine (ref <2 [<0.5 mo], <1 [0.5–1 y],
<0.5 [>1 y] mmol/mol Crea)
NA NA NA NA NA ,1a ,1 at 1 mo, 1.3
at 2 mo
,1 ,1 ,1 NA
CSF (ref < 0.1 mmol/L) NA Normal NA NA NA NA NA NA NA NA NA
Pipecolic acid
Plasma (ref 3.75–10.8 [<1 wk],
0.7–2.46 [>1 wk] mmol/L)
NA Normal NA Normala Normal Normala NA NA NA 20 at 7 mo Normal
Urine NA NA NA Normala Normal NA Elevated Normal Normal NA Normal
CSF (ref 0.009–0.12 mmol/L) NA Normal NA NA NA NA NA NA NA NA NA
Lactate
Plasma (ref <2 mmol/L) NA NA NA 2.2 NA NA 12.4 11 14.9 NA NA
Amino acids (plasma)
Threonine, mmol/L NA 82 on day 3 (ref
22.2–52.6)
NA Normal NA Normal Normal Normal Normal Normal Normal
Glycine, mmol/L NA Normal NA Normal NA Normal 1,102 at birth
(ref 232–740)
Normal Normal Normal Normal
Arginine, mmol/L NA Normal NA 142 at 9 wk
(ref 6–130)
NA Normal Normal Normal Normal Normal Normal
Neurotransmitters
HVA NA Normal NA Normal NA NA NA NA NA Normal Normala
5-HIAA, nmol/L NA 891 on day
3 (ref 150–800)
NA Normal NA NA NA NA NA Normal Normala
3-0-methyl dopa, nmol/L NA 3,879 on day 3
(ref ,300)
NA Normal NA NA NA NA NA Normal Normala
Organic acids
Urine NA Elevated lactate
on day 2
NA Normal NA NA Elevated lactate
on day 2
Elevated lactate
on day 1
Normal NA Normal
Vanillactate
Urine NA NA NA NA NA NA NA NA NA Elevated at 7 mo NA
Abbreviations: AASA 5 a-aminoadipic semialdehyde; HVA 5 homovanillic acid; HIAA 5 hydroxindoleacetic acid; NA 5 not available; ref 5 reference.
aOn pyridoxine.
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was proven by heterozygous state in both parents and in
2 unaffected siblings of family 1. No material of the
deceased siblings 1a and 2a and of the unaffected sibling
of patient 2a and patient 3 was available for molecular
testing.
The novel missense mutations, p.Arg225His as
well as p.Arg141Cys, affect arginine residues present-
ing codons with the potential CpG DNAmethylation
site with an increased probability for mutational
events. The novel deletion c.279_290del is located
in the b-strand S2 of the PNPO protein. None of
the novel mutations could be found in 100 control
alleles. In addition, a total of 4 polymorphisms were
identified (table 3). Among the 4 polymorphisms,
c.347G.A had a high prevalence of 2.7% on 200
alleles tested.
Expression studies in CHO-K1 cell lines (Laboratory of
Metabolic Diseases Graz). In vitro studies in CHO-K1
cell lines showed that transfection with wild-type
PNPO produced readily measurable enzyme activity.
Transfection with DNA containing the p.Arg225His
mutation resulted in undetectable enzyme activity
(n 5 10). Transfection with DNA containing the
p.Arg141Cys resulted in reduced enzyme activity
of ;51% of that of wild-type (n 5 10). Transfection
with DNA containing the c.279_290del resulted in
undetectable enzyme activity (n 5 10).
DISCUSSION With respect to their clinical presenta-
tion, our 11 patients with pyridoxine-responsive
PNPO mutations were indistinguishable from
previously reported cases with exclusive PLP response.
In the 24 patients with PNPO deficiency harboring a
total of 10 different mutations published to date,1,3–6,8–10
only 2 have shown a partial pyridoxine response with
improvement when switched to PLP.1,8 In contrast, all
9 patients harboring specific novel PNPO mutations
published in this article had partial or even complete
pyridoxine response and were thus initially suspected to
have antiquitin deficiency by their referring physician.
Antiquitin deficiency was excluded by normal AASA
or PA concentrations in all families and by wild-type
sequence of the ALDH7A1 gene in every living patient.
In antiquitin deficiency, 85% of a larger patient series
had prompt response to the first administration of
pyridoxine.11 In this series, only 4 out of 9 patients
(44%) had a prompt initial pyridoxine response, while
2 had delayed effects with reduction of seizures over
days, 2 by effect on EEG only, and 2 had failure of
initial response in the neonatal period. Patient 2b
underwent a formal pyridoxine withdrawal with rapid
recurrence of seizures 12 hours after last intake, while in
2 cohorts of patients with confirmed antiquitin
deficiency interval to seizure recurrence ranged from
24 hours to weeks.12–14 Complete seizure freedom or
occasional seizures on PLP monotherapy have so
far been reported in single patients with PNPO
deficiency.10,14,15 Of interest, in our cohort of patients
with pyridoxine-responsive PNPOmutations, 6 patients
(66%) were completely seizure-free on pyridoxine
Table 3 Mutation analysis of the PNPO gene in 11 patients from 7 unrelated families: Reference sequence NM_018129.3
Patient Mutation Exon Polymorphisms Country of origin
1a NA NA Kosovo
1b [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 [c.347G.A] homozygote
[IVS6-26A.G] homozygote
[c.552G.A] homozygote
2a NA NA Albania
2b [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 [c.347G.A] homozygote
[c.552G.A] homozygote
2c [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 [c.347G.A] homozygote
3 [c.421C.T] 1 [c.279_290del]; (p.Arg141Cys 1 p.Ser93Ser, Ala94_Leu97del) 5/3 [c.347G.A] [IVS6-26A.G] Canada
[c.552G.A] homozygote
[c.165C.T]
4a [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 [c.552G.A] homozygote Kosovo
4b [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 [c.552G.A] homozygote
5 [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 [c.552G.A] homozygote Serbia
6 [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 Unknown
7 [c.674G.A] 1 [c.674G.A]; (p.Arg225His 1 p.Arg225His) 7 c.[347G.A] homozygote Former Yugoslavia (no details)
[c.552G.A] homozygote
Abbreviation: NA 5 not available.
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monotherapy, in some with only 2 single doses a day.
Still, these pyridoxine-responsive PNPO mutations
cannot be regarded as “mild,” as 2 siblings have died
from epileptic encephalopathy in the absence of
continuous pyridoxine treatment and 2 patients with
treatment delay are severely handicapped. No patient
in this study received PLP prior to the identification
of the PNPO mutation. As a result of our genetic
findings, 2 patients, who by then still had occasional
seizures, were switched to PLP. Both patients
developed status epilepticus as soon as pyridoxine was
replaced by an identical dose of PLP at the scheduled
Figure Mutations found in the human PNPO gene
(A) Left column: deletion c.279_290del (p.Ser93Ser, Ala94_Leu97del) in exon 3. Right column: restriction digest test: PCR
with loss of restriction site (restriction site alteration—Cac8l). Patient 3 and his father are heterozygous. (B) Left column:
missense mutation c.421C.T (p.Arg141Cys) in exon 5. Right column: restriction digest test: PCR with loss of restriction
site upon introduction of a mismatch primer (restriction site alteration—MvnI*). Patient 3 and his mother are heterozygous.
(C) Left column: missense mutation c.674G.A (p.Arg225His) in exon 7. Right column: restriction digest test: PCR with
introduction of a restriction site (restriction site alteration 1 BspMI). Patients 1b, 2b, and 2c (4a, 4b, 5, 6, and 7 not shown)
were homozygous. Heterozygote (Hz) state as identified in parents of families 1, 2, 4, 5, 6, and 7. F 5 father; M 5 mother;
MW 5 molecular weight; P 5 patient; un 5 undigested PCR; wt 5 wild-type.
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time of medication administration. Thus all patients
continued on pyridoxine with or without comedication
of other antiepileptic drugs (table 1).
This phenotype of pyridoxine responsiveness was
exclusively associated with 3 novel mutations of the
PNPO gene, namely a deletion c.279_290del in exon 3,
a missense mutation p.Arg141Cys in exon 5, and
another missense mutation p.Arg225His mutation in
exon 7 of the PNPO gene. In order to interpret the
damaging effect of these novel mutations, we applied
the computational software tools SIFT16 and Poly-
Phen-2,17 which analyze the impact of sequence varia-
tions on protein function. In addition, pathogenicity of
the novel mutations was assessed by expression studies
in CHO-K1 cells for all 3 mutations.
The novel mutation p.Arg225His in exon 7 was
present on 16/18 alleles and is affecting the PLP bind-
ing site in a strongly conserved region of the PNPO
protein (table e-2).18 Prediction results by PolyPhen-2
about the probability of damage revealed a maximal
score of 1.0 by HumDiv and 0.999 by HumVar. Pre-
diction results by SIFT gave a maximal probability for
disturbed protein function of 0.0. Multiple sequence
alignment showed 100% conservation among 60 dif-
ferent species by PolyPhen-2 and a high median
sequence conservation of 3.02 among 33 different spe-
cies by SIFT.
The novel mutation p.Arg141Cys in exon 5 was
found in 1 compound heterozygous patient and is part
of the highly conserved region carrying the FMN bind-
ing site, which by forming 2 hydrogen bonds between
the molecule and the enzyme plays an important
role in the enzymatic reaction.18 Prediction results by
PolyPhen-2 revealed a maximal score of 1.0 by Hum-
Div and 0.998 by HumVar. Prediction results by SIFT
gave a maximal probability for disturbed protein function
of 0.0.Multiple sequence alignment showed conservation
in 54 out of 55 different species by PolyPhen-2 and a
high median sequence conservation of 3.03 by SIFT.
The novel deletion c.279_290del in exon 3 was
found in compound heterozygosity in 1 patient and
leads to the loss of a highly conserved residue, arginine
95, most probably inhibiting the formation of the
b-strand. None of the lost amino acids is involved in
pyridoxine 59-phosphate/pyridoxamine 59-phosphate
oxidation.18 Although there is no frameshift in the pro-
tein sequence, one can speculate that the protein struc-
ture is not stable and no functional enzyme is translated.
Expression studies in transfected CHO-K1 cell lines
revealed a 50% reduced PNPO enzymatic activity for
mutation p.Arg141Cys, while transfection with p.Ar-
g225His and c.279_290del led to no detectable enzy-
matic activity in our in vitro expression system. No
Western blot studies have been performed to show if
mutant proteins were expressed and processed. Still, these
results underline the pathogenicity of each respective
mutation butmay be an underestimate of in vivo residual
enzyme activity due to potential stabilization of mutant
PNPO protein in its natural environment. The observed
pyridoxine response suggests some residual enzymatic
activity for p.Arg225His found in homozygous form in
8 patients. Alternatively, pyridoxine could have a chap-
eron effect and preserve the mutant PNPO protein from
premature decay.
As 6 out of all families carrying the p.Arg225His mu-
tations derive from former Yugoslavia, it may well repre-
sent a founder mutation. The main function of PNPO is
PLP formation,18 which serves as an essential cofactor in
over 120 enzyme reactions in amino acid and neuro-
transmitter metabolism. More recently, a role of PNPO
in intracellular recycling of cofactor degraded enzymes18
and channeling of PLP to its various apoenzymes has
been described.19 In order to protect cells from PLP
toxicity, PLP has a strong inhibitory effect on PNPO
activity.20 The observed status epilepticus in 2 patients
homozygous for the novel p.Arg225His mutation sug-
gests that the PNPO protein carrying the mutation
p.Arg225His might be completely inhibited by the
administration of PLP. Further in vitro studies are
needed to prove this hypothesis.
While antiquitin deficiency is biochemically charac-
terized by a specific compound, AASA, or less specifically
by elevated PA in urine, plasma, and CSF,2,21,22 PNPO
deficiency lacks a specific biomarker. Low PLP concen-
trations in CSF have previously been considered a hall-
mark of PNPO deficiency,23 but can be found in several
inborn errors affecting PLP metabolism,24 are thus
unspecific, and require sampling prior to PLP or pyri-
doxine administration. Secondary deficiency of homova-
nillic acid hydroxyindoleacetic acid and increased
concentrations of 3-methoxytyrosine have been described
in several PNPO patients1,5 but are only present in about
half of all PNPOpatients.25 Still, these secondary findings
can be helpful in raising the suspicion of a disorder related
to cerebral vitamin B6 deficiency. Of interest, one patient
from our series had elevated concentrations of neuro-
transmitter amine metabolites. This seems paradoxical
but has so far been reported in 3 other patients with
PNPO deficiency.4,6,15 Elevation of urinary vanillactate
due to the buildup of L-dopa is present in about 80%
of PNPO patients and has been raised in the one patient
from this series who underwent determination. Recently,
distinct B6 vitamer profiles have been described in the
plasma of patients with PNPO deficiency, even when on
treatment.26 No measurement of PLP in CSF or inves-
tigation of B6 vitamer profiles in plasma have been per-
formed in any patient presented in this study.
The findings of our study have several important
implications for our clinical practice. First, they shift
the paradigm of exclusive PLP responsiveness of pa-
tients with PNPO deficiency and contradict the strat-
egy of using PLP instead of pyridoxine as the first-line
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vitamin to test for all inborn errors with vitamin
B6-responsive seizures. Second, they underline the
importance of testing for PNPO mutations in the pres-
ence of a pyridoxine response but normal biomarkers,
especially those of antiquitin deficiency or other vitamin
B6-dependent epilepsies that can manifest in the neo-
natal period such as severe congenital hypophosphata-
sia.27–29 Considering the high preponderance of birth
asphyxia in antiquitin as well as PNPO deficiency, a
standardized trial with pyridoxine and PLP should be
performed routinely in neonates with seizures irrespec-
tive of the birth history. Third, this study suggests that
patients with pyridoxine-responsive mutations in the
PNPO gene might be a prevalent group, considering
a total of 24 patients with PLP-responsive PNPO mu-
tations published to date and 11 new patients with
pyridoxine-responsive mutations of the PNPO gene.
The challenge of recognizing a delayed pyridoxine effect
and current lack of specific biomarkers puts this patient
group at a considerable risk of remaining undiagnosed.
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Free Michael J. Fox DVD, Video on Parkinson’s Disease
The AAN and the American Brain Foundation present actor and Parkinson’s disease patient
Michael J. Fox hosting Parkinson’s Disease: A Guide for Patients and Families. This new patient
education video is now available free to members and the public, either on DVD or online. The
free DVD can be ordered while supplies last by visiting AAN.com/view/PatientEducationVideos or
calling (800) 879-1960. The video can be viewed online at YouTube.com/AANChannel with other
patient education DVDs produced by the AAN.
The Premier Event for the Latest Research on Concussion
Registration is now open for The Sports Concussion Conference—the premier event on sports
concussion from the American Academy of Neurology—set for July 11 through 13, 2014, at the
Sheraton Chicago Hotel & Towers in Chicago. You won’t want to miss this one-of-a-kind oppor-
tunity to learn the very latest scientific advances in diagnosing and treating sports concussion, post-
concussion syndrome, chronic neurocognitive impairment, and controversies around gender issues
and second impact syndrome from the world’s leading experts on sports concussion. Early regis-
tration ends June 9, 2014. Register today at AAN.com/view/ConcussionConference.
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